Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY
Rates of COVID-19-related hospitalisation and death were substantially lower after bivalent original/omicron BA.1 mRNA booster vaccine than in people who remained unboosted. Apparent protection against fracture suggests some unmeasured confounding. Outcomes appeared similar for the Moderna and Pfizer-BioNTech vaccines.
Authors
- Rachel Denholm (ORCID: https://orcid.org/0000-0002-8067-5440)
- Paul Madley‐Dowd (ORCID: https://orcid.org/0000-0003-2932-9486)
- Jonathan A.C. Sterne
- Tom M. Palmer
- Elsie M.F. Horne
- Venexia Walker
Institutions
- University Hospitals Bristol NHS Foundation Trust (GB)
- Bristol City Council (GB)
- University of Bristol (GB)
- University of Oxford (GB)
- NIHR Bristol Biomedical Research Centre (GB)
Publication Details
- Journal
- Vaccine
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1016/j.vaccine.2026.128276
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00